Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, KalVista Pharmaceuticals Inc’s stock clocked out at $15.23, up 1.53% from its previous closing price of $15.0. In other words, the price has increased by $1.53 from its previous closing price. On the day, 1.8 million shares were traded. KALV stock price reached its highest trading level at $15.47 during the session, while it also had its lowest trading level at $14.94.
Ratios:
To gain a deeper understanding of KALV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.22. In the meantime, Its Debt-to-Equity ratio is 16.62 whereas as Long-Term Debt/Eq ratio is at 16.34.
Upgrades & Downgrades
In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19. On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30. On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 08 ’25 when Palleiko Benjamin L sold 7,294 shares for $16.51 per share. The transaction valued at 120,424 led to the insider holds 424,520 shares of the business.
Sweeny Nicole sold 3,813 shares of KALV for $51,289 on Nov 24 ’25. The Chief Commercial Officer now owns 39,728 shares after completing the transaction at $13.45 per share. On Nov 24 ’25, another insider, Piekos Brian, who serves as the Chief Financial Officer of the company, sold 4,471 shares for $13.45 each. As a result, the insider received 60,139 and left with 10,529 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 769820032 and an Enterprise Value of 743241024. For the stock, the TTM Price-to-Sale (P/S) ratio is 538.34 while its Price-to-Book (P/B) ratio in mrq is 45.28. Its current Enterprise Value per Revenue stands at 521.207 whereas that against EBITDA is -3.683.
Stock Price History:
The Beta on a monthly basis for KALV is -0.14, which has changed by 0.7248018 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $17.30, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 15.88%, while the 200-Day Moving Average is calculated to be 17.72%.
Shares Statistics:
It appears that KALV traded 1.41M shares on average per day over the past three months and 1134860 shares per day over the past ten days. A total of 50.54M shares are outstanding, with a floating share count of 37.84M. Insiders hold about 25.28% of the company’s shares, while institutions hold 97.71% stake in the company. Shares short for KALV as of 1764288000 were 14426123 with a Short Ratio of 10.23, compared to 1761868800 on 13328249. Therefore, it implies a Short% of Shares Outstanding of 14426123 and a Short% of Float of 32.11.
Earnings Estimates
. The current rating of KalVista Pharmaceuticals Inc (KALV) reflects the combined expertise of 7 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.43 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1.65 and -$3.76 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.09, with 8.0 analysts recommending between -$0.44 and -$2.73.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $28.33M. There is a high estimate of $39M for the next quarter, whereas the lowest estimate is $15.5M. Based on 9 analysts’ estimates, the company’s revenue will be $120.05M in the next fiscal year. The high estimate is $242.2M and the low estimate is $33.71M.
